logo
Blood test to predict tumor recurrence of advanced skin cancer called highly accurate

Blood test to predict tumor recurrence of advanced skin cancer called highly accurate

Yahoo15-04-2025

ST. PAUL, Minn., April 15 (UPI) -- New York University researchers say a simple, gene-based blood test has shown to be highly accurate in predicting whether some stage III melanoma patients are likely to suffer recurrences of cancerous tumors.
The new test looks for a specific type of DNA shed by tumors of stage III melanoma patients who, if found, indicates a strong likelihood their cancer will return in the aftermath of lymph node surgery, according to the authors of a study published Tuesday in The Lancet Oncology.
Stage III melanoma is an advanced form of skin cancer in which the malignancy has spread beyond the original site to nearby lymph nodes or surrounding tissue, requiring aggressive treatment such as surgery, immunotherapy or targeted therapy to restrict its progression.
Using the new test, an analysis of hundreds of blood plasma samples taken from stage III melanoma patients with mutated BRAF genes -- who make up about half of all skin cancer sufferers -- determined that approximately 80% of those who had evidence of circulating tumor DNA, or ctDNA, in their samples eventually went on to develop recurrences of their cancers.
The research was funded by the Swiss pharmaceutical giant Novartis, maker of the melanoma-inhibiting drugs Tafinlar and Mekinist.
The high level of prediction accuracy means oncologists and dermatologists may soon have a valuable new tool to quickly and easily tell which patients are most likely to respond well to follow-on "adjuvant" therapy after surgery, according to Dr. David Polsky, the Alfred W. Kopf Professor of Dermatologic Oncology in the Ronald O. Perelman Department of Dermatology at NYU, as well as an advisory board member for Novartis.
"We think [patients with resected stage III melanoma] would most likely benefit from ctDNA measurements shortly after their surgery -- [for example} within 12 weeks or less as was done in this study -- and periodically thereafter," Polsky told UPI in emailed comments.
Those patients, he said, would for the first time have a "clear, direct measure of the disease itself" -- a significant improvement over the current method of tissue-based analyses of tumor cells that can only suggest the likelihood of recurrence.
Potential benefits
Where the new test could have particularly strong benefits is among melanoma patients who have undergone successful lymph node resections and are currently cancer-free, but who choose to forego follow-up drug therapy due to financial burdens or other reasons. An accurate test for ctDNA could identify which of them are at higher risk and most in need of adjuvant therapy, Polsky said.
"Also, we did have samples from some patients who completed a year of treatment and then stopped their treatment according to the protocol rules," he added. "In some of those patients we detected ctDNA beginning mostly three months after stopping treatment.
"So, another group of patients who might benefit from the test are those patients with resected stage III melanoma who stop their adjuvant therapy and would like to have a blood test to help identify melanoma recurrence should it happen."
Although the test did not detect ctDNA in every patient who eventually recurred, when the test was positive, nearly everybody in that group developed a recurrence detectable on a radiographic scan, Polsky said, adding, "We're hoping that with additional study this test can become part of the routine work-up for patients with melanoma that has escaped the skin and spread to other parts of the body."
Doctors who see a positive ctDNA test result in patients carrying a mutation of the BRAF gene could then take proactive steps, such as ordering a computed tomography, or CT, scan ahead of schedule or requesting a more sensitive PET-CT scan, the authors suggest.
Latest evidence
The study "adds to the increasing evidence that circulating tumor DNA has a useful role in patients where the cancer has been surgically resected and patients are at high risk of recurrence," said Dr. Alastair Greystoke, an oncologist at the Northern Center for Cancer Care in Newcastle-upon-Tyne, England, and an authority on genetic cancer biomarkers. He was not involved in the NYU study.
"[The authors] showed with a robust and relatively cheap blood test that you could predict patients who were likely to relapse following surgery for melanoma that had spread to the lymph nodes, where we hope patients are cured but there is a high chance it will come back," Greystoke told UPI.
"At the moment, these patients are offered extra treatment with targeted drugs or immunotherapy, which reduce the chance of recurrence, but these drugs are expensive can be associated with significant and life changing side-effects and are not needed by all."
Overall, the noted oncologist added, "this study adds to the utility of ctDNA, moving it strongly into the detection and measurement of minimal residual disease to inform decision-making in patients who have had surgery for BRAF-mutated melanoma. It is likely we will see increasing use in this and other tumor types."
Meanwhile, the leader of the world's largest private nonprofit funder of melanoma research told UPI the results of the NYU study are "exciting" and part of a "promising" front in the fight against the disease.
"CtDNA monitoring appears promising to help guide treatment escalation, switching, or de-escalation," said Dr. Marc Hurlbert, CEO of the Melanoma Research Alliance.
Evidence is mounting that keeping an eye on levels of tumor-related genetic material can help in many areas of melanoma treatment, such as identifying patients at high risk of recurrence, monitoring response to treatments, helping to guide treatment selection, signaling "when a switch from an approved agent to a clinical trial might be necessary, and lastly to augment imaging tests for monitoring for disease recurrence," he said.
Hurlbert noted his alliance has funded previous research on analyzing bloodstream biomarkers to detect cancer risk, including an study published this month in which scientists applied low-cost, whole-genome sequencing techniques to ctDNA to identify risks of mutations.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Supportive doctors help LGBTQ patients stay healthier
Supportive doctors help LGBTQ patients stay healthier

UPI

timean hour ago

  • UPI

Supportive doctors help LGBTQ patients stay healthier

Marchers carry a pride banner in the WorldPride 2025 Parade in Washington on Saturday. A study shows supportive care boosts the health of the LGBTQ community and cuts costs. File Photo by Leigh Vogel/UPI | License Photo June 10 (UPI) -- When LGBTQ+ patients are unsure if they can be open about their identity and related health needs, it becomes more difficult for them to access high-quality health care. In our recently published research, my colleagues and I found that how LGBTQ+ people are treated at the doctor's office has a measurable effect on whether they stay up to date with lifesaving preventive care like flu shots, colorectal cancer screenings and HIV testing. Results of affirming care We examined how LGBTQ+ adults rated their health care provider across three areas: LGBTQ+ cultural competency, such as if providers used inclusive language on forms and in person; LGBTQ+ clinical competency, such as their doctor's knowledge on all aspects of their health; and experiences of discrimination, such as being told to seek care elsewhere. After analyzing survey data on the experiences of more than 950 LGBTQ+ adults from across the U.S., we saw that three clear patterns emerged. First, 34% of participants reported having positive health care experiences - meaning their providers were culturally and clinically competent about LGBTQ+ health needs, and did not discriminate against them. These patients were more likely to be up to date on at least one preventive service recommended by the U.S. Preventive Services Task Force, compared to those receiving neutral or discriminatory care. Second, 60% of participants reported having neutral experiences, when their providers were clinically competent about LGBTQ+ health needs and didn't discriminate against them, but were not culturally competent. These patients were 43% less likely to get an HIV test compared to patients reporting affirming care. Third, 6% of participants reported experiencing discrimination, when their providers were neither culturally nor clinically competent on LGBTQ+ health. These patients were 24% less likely to get a colorectal cancer screening compared to patients reporting affirming care. Most LGBTQ+ adults in our study reported neutral or even discriminatory care, which leads to avoidable health risks and higher costs for the health system. This provides additional evidence that being supportive of LGBTQ+ patients has measurable improvements for health outcomes. Why preventive care matters Preventive care saves lives and saves money. When diseases like colorectal cancer or HIV are caught early, treatments are often simpler, more effective and less expensive. When LGBTQ+ patients are made to feel unwelcome or unsafe, we found that they are less likely to get routine preventive care, ultimately driving up long-term costs across the health system. States like North Carolina and Georgia that have more health systems participating in the Human Rights Campaign's Healthcare Equality Index, which evaluates policies and practices around LGBTQ+ care, had higher rates of LGBTQ+ patients reporting positive care experiences compared to states with few participating health systems, such as Tennessee and Alabama. Other researchers have found that health systems participating in the Healthcare Equality Index have lower rates of nurse burnout and better quality of care, along with higher patient satisfaction among all patients. Public health in crisis This study was originally funded by the National Institute on Aging, but it was among the first LGBTQ+-focused projects terminated by the Trump administration in its efforts to eliminate "gender ideology." Our team has continued the work independently to ensure that the over 1,250 participants who already shared their experiences and data would not have this information sit idly. Our findings reinforce what many LGBTQ+ patients already know - nonjudgmental and competent care is not a luxury, but a public health necessity. University of Illinois Chicago. This article is republished from The Conversation under a Creative Commons license. Read the original article. The views and opinions expressed in this commentary are solely those of the author.

41. Rad AI
41. Rad AI

CNBC

time7 hours ago

  • CNBC

41. Rad AI

Founders: Doktor Gurson (CEO), Jeff ChangLaunched: 2018Headquarters: San FranciscoFunding: $143 millionValuation: $528 millionKey Technologies: Artificial intelligence, cloud computing, deep neural networks/deep learning, generative AI, machine learningIndustry: Health carePrevious appearances on Disruptor 50 list: 0 Radiologist burnout is a condition that Rad AI co-founder Jeff Chang has long experience with — arguably, longer than any other radiology specialist has ever witnessed. The youngest radiologist and second youngest doctor in U.S. history, Chang started medical school at 16 at New York University and worked long night shifts as an emergency room radiologist for a decade. The stress hasn't changed within his profession. With the vast majority of radiologists feeling overworked or at their limit, Rad AI is focused on using generative artificial intelligence to save time and enhance productivity. Rad AI offers products designed to streamline workflow for radiologists, Rad AI Reporting and Rad AI Impressions. Rad AI Reporting generates imaging reports based on radiologists stating their findings from scans into a microphone or software system. By combining speech recognition with machine learning algorithms, it can also create templates that match individual radiologists' language and style preferences. Rad AI Impressions provides a summary of what a patient's image shows, saving radiologists over an hour per shift, according to the company, time that can be put back into patient care and burnout prevention. Its AI models also identify follow-up recommendations from patient reports, and can automatically send communication to patients, which Rad AI says can increase needed follow-up appointments by as much as 40%. A decade ago, experts were predicting radiology would be one of the first professions entirely replaced by AI. AI pioneer Geoffrey Hinton of the University of Toronto, and formerly Google, was among those quoted as saying radiologists should no longer be trained. Hinton recently told the New York Times that he was wrong, and while AI is great at interpreting imagery, it is a profession where it looks like AI and human doctors will be working together for much longer. Rad AI's core reporting and imagery tools are designed to be reviewed and signed off by the radiologist. In the case of any system errors, the radiologist will have the final look at the patient's report and impression. The future for Rad AI is looking bright, as the company is currently working with half of all health systems and radiology practices in the United States, including recent deals with the Mayo Clinic, Cleveland Clinic, Yale New Haven and Cincinnati Children's Hospital. It also has recent partnerships with tech and health-care giants Google and Bayer.

Parkinson's Disease Market Research Report 2025-2035: Market Trends, Epidemiology Analysis, Regulatory Framework, Clinical Trial Analysis, Market Dynamics
Parkinson's Disease Market Research Report 2025-2035: Market Trends, Epidemiology Analysis, Regulatory Framework, Clinical Trial Analysis, Market Dynamics

Yahoo

time8 hours ago

  • Yahoo

Parkinson's Disease Market Research Report 2025-2035: Market Trends, Epidemiology Analysis, Regulatory Framework, Clinical Trial Analysis, Market Dynamics

Parkinson's disease (PD) is a progressive disorder affecting movement control due to the degeneration of dopamine-producing neurons. While there is no cure, advancements in gene therapy and other treatments aim to slow disease progression. With a rising global prevalence, the competitive market seeks innovative, affordable solutions from key players like AbbVie, GSK, and Novartis, targeting both motor and non-motor symptoms. Emerging trends include precision medicine, biologics, and digital health solutions, reshaping global PD management. Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Parkinson's Disease Market - A Global and Regional Analysis: Focus on Drug Class, Country, and Region - Analysis and Forecast, 2025-2035" report has been added to Parkinson's disease is a progressive condition, there is a significant opportunity for companies to capitalize on the demand for treatments that not only manage symptoms but also slow or halt disease progression. With ongoing advancements in gene therapies, stem cell-based treatments, and biologic drugs, the competition is intensifying, as companies strive to offer more effective, personalized, and affordable solutions to meet the growing needs of patients. The market is also being shaped by the rising prevalence of Parkinson's disease, driven in part by the global aging population, making it a critical area for investment and global Parkinson's disease market is highly competitive, with several major pharmaceutical companies leading the way in the development of innovative treatments. The global Parkinson's disease (PD) market is highly competitive, with several major pharmaceutical and biotechnology companies vying to develop and commercialize effective treatments for the companies are focused on both symptomatic management and disease-modifying therapies, with a strong emphasis on innovation. Some of the key players in the market include AbbVie, Inc., Merck & Co., Inc., GlaxoSmithKline (GSK), Novartis AG, and Teva Pharmaceutical Industries Ltd. These companies compete through a combination of novel drug formulations, advanced delivery systems, and surgical interventions like deep brain stimulation (DBS).One of the key drivers of the Parkinson's disease (PD) market is the advancement in treatment options, particularly the development of disease-modifying therapies. While current treatments primarily focus on managing symptoms, there is a growing emphasis on targeting the underlying causes of Parkinson's, such as the loss of dopamine-producing neurons. Innovative treatments like gene therapy, cell-based therapies, and novel drug formulations that aim to slow or halt disease progression are generating significant interest in the the increasing prevalence of Parkinson's disease, driven by an aging global population, is fuelling demand for effective therapies. As more people are diagnosed, the need for new and improved treatments continues to grow, driving research and investment into Parkinson's disease therapies. Moreover, advances in diagnostics that enable earlier detection and better disease monitoring are also helping to increase market opportunities for new the growth of the Parkinson's disease (PD) market, several challenges continue to hinder its expansion and overall effectiveness. One major issue is the lack of a cure, as current treatments primarily focus on symptom management rather than halting or reversing the disease. While levodopa and other medications can alleviate motor symptoms, they do not address the underlying neurodegeneration or slow disease progression. Another challenge is the side effects of long-term treatment, especially with levodopa, which can lead to motor fluctuations and dyskinesia (involuntary movements) over high treatment costs for advanced therapies, such as gene therapy or deep brain stimulation (DBS), create significant financial barriers for patients, limiting access to cutting-edge treatments, particularly in lower-income regions. The complexity of early diagnosis and lack of biomarkers for Parkinson's also complicates the timely initiation of treatment. Furthermore, there is a limited understanding of the exact causes of the disease, making it difficult to develop disease-modifying therapies. Finally, the aging global population is driving an increased incidence of Parkinson's, placing added pressure on healthcare systems to provide adequate care and treatment options. Companies Featured GlaxoSmithKline Merck & Co., Inc. AbbVie, Inc. Boehringer Ingelheim UCB S.A. Teva Pharmaceutical Industries Ltd. Bausch Health Acadia Pharmaceuticals Lundbeck Amneal Pharmaceuticals LLC Mitsubishi Tanabe Pharma Key Topics Covered:1. Global Parkinson's Disease Market: Industry Outlook1.1 Introduction1.2 Market Trends1.3 Epidemiology Analysis1.4 Regulatory Framework1.5 Clinical Trial Analysis1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Challenges1.6.4 Market Opportunities2. Global Parkinson's Disease Market, by Drug Class, ($Million), 2023-20352.1 Overview2.2 MAO-B Inhibitors2.3 COMT inhibitors2.4 Anticholinergics2.5 Others3. Global Parkinson's Disease Market (Region), ($Million), 2023-20353.1 North America3.1.1 Key Findings3.1.2 Market Dynamics3.1.3 Market Sizing and Forecast3.1.3.1 North America Parkinson's Disease Market, by Country3.1.3.1.1 U.S.3.1.3.1.2 Canada3.2 Europe3.2.1 Key Findings3.2.2 Market Dynamics3.2.3 Market Sizing and Forecast3.2.3.1 Europe Parkinson's Disease Market, by Country3.2.3.1.1 Germany3.2.3.1.2 U.K.3.2.3.1.3 France3.2.3.1.4 Italy3.2.3.1.5 Spain3.2.3.1.6 Rest-of-Europe3.3 Asia Pacific3.3.1 Key Findings3.3.2 Market Dynamics3.3.3 Market Sizing and Forecast3.3.3.1 Asia Pacific Parkinson's Disease Market, by Country3.3.3.1.1 China3.3.3.1.2 Japan3.3.3.1.3 India3.3.3.1.4 South Korea3.3.3.1.5 Australia3.3.3.1.6 Rest-of- Asia Pacific3.4 Rest of the World3.4.1 Key Findings3.4.2 Market Dynamics3.4.3 Market Sizing and Forecast4. Global Parkinson's Disease Market: Competitive Landscape and Company Profiles4.1 Key Development and Strategies4.1.1 Mergers and Acquisitions4.1.2 Synergistic Activities4.1.3 Business Expansions and Funding4.1.4 Product Launches and Approvals4.1.5 Other Activities4.2 Company Profiles4.2.1 Overview4.2.2 Top Products / Product Portfolio4.2.3 Top Competitors4.2.4 Target Customers/End-Users4.2.5 Key Personnel4.2.6 Analyst View5. Research MethodologyFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store